

Joseph I Friedman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2653111/publications.pdf>

Version: 2024-02-01

31
papers

3,566
citations

257450

24
h-index

501196

28
g-index

34
all docs

34
docs citations

34
times ranked

5740
citing authors

#	ARTICLE	IF	CITATIONS
1	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. <i>Nature Genetics</i> , 2017, 49, 27-35.	21.4	838
2	White Matter Changes in Schizophrenia. <i>Archives of General Psychiatry</i> , 2003, 60, 443.	12.3	761
3	Diffusion Tensor Imaging Findings in First-Episode and Chronic Schizophrenia Patients. <i>American Journal of Psychiatry</i> , 2008, 165, 1024-1032.	7.2	227
4	The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease. <i>Biological Psychiatry</i> , 1999, 46, 1243-1252.	1.3	177
5	A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. <i>Biological Psychiatry</i> , 2002, 51, 349-357.	1.3	170
6	Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. <i>Psychopharmacology</i> , 2004, 174, 45-53.	3.1	164
7	Pharmacologic strategies for augmenting cognitive performance in schizophrenia. <i>Biological Psychiatry</i> , 1999, 45, 1-16.	1.3	139
8	Diffusion Tensor Imaging in Schizophrenia. <i>Biological Psychiatry</i> , 2006, 60, 1181-1187.	1.3	115
9	Guanfacine Treatment of Cognitive Impairment in Schizophrenia. <i>Neuropsychopharmacology</i> , 2001, 25, 402-409.	5.4	103
10	Brain Metabolite Abnormalities in the White Matter of Elderly Schizophrenic Subjects: Implication for Glial Dysfunction. <i>Biological Psychiatry</i> , 2007, 62, 1396-1404.	1.3	89
11	Brain Imaging Changes Associated With Risk Factors for Cardiovascular and Cerebrovascular Disease in Asymptomatic Patients. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1039-1053.	5.3	82
12	The Effects of Hypertension and Body Mass Index on Cognition in Schizophrenia. <i>American Journal of Psychiatry</i> , 2010, 167, 1232-1239.	7.2	76
13	Cognition in schizophrenia. <i>Current Psychiatry Reports</i> , 2001, 3, 423-428.	4.5	74
14	Correlates of Change in Functional Status of Institutionalized Geriatric Schizophrenic Patients: Focus on Medical Comorbidity. <i>American Journal of Psychiatry</i> , 2002, 159, 1388-1394.	7.2	69
15	Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia. <i>JAMA Psychiatry</i> , 2021, 78, 510.	11.0	63
16	Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls. <i>BMC Psychiatry</i> , 2007, 7, 25.	2.6	61
17	Pharmacological Treatments of Non-Substance-Withdrawal Delirium: A Systematic Review of Prospective Trials. <i>American Journal of Psychiatry</i> , 2014, 171, 151-159.	7.2	57
18	Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areas. <i>Biological Psychiatry</i> , 2000, 47, 962-968.	1.3	56

#	ARTICLE	IF	CITATIONS
19	A Pilot Study of Adjunctive Atomoxetine Treatment to Second-Generation Antipsychotics for Cognitive Impairment in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 59-63.	1.4	49
20	Temporal characteristics of tract-specific anisotropy abnormalities in schizophrenia. <i>NeuroReport</i> , 2008, 19, 1369-1372.	1.2	38
21	Potential Noradrenergic Targets for Cognitive Enhancement in Schizophrenia. <i>CNS Spectrums</i> , 2004, 9, 350-356.	1.2	32
22	Pimozide Augmentation of Clozapine Inpatients with Schizophrenia and Schizoaffective Disorder Unresponsive to Clozapine Monotherapy. <i>Neuropsychopharmacology</i> , 2011, 36, 1289-1295.	5.4	32
23	Modifiable factors associated with postoperative delirium after hip fracture repair. <i>European Journal of Anaesthesiology</i> , 2020, 37, 649-658.	1.7	29
24	Brodmann area analysis of white matter anisotropy and age in schizophrenia. <i>Schizophrenia Research</i> , 2011, 130, 57-67.	2.0	28
25	Copy Number Variation in Syndromic Forms of Psychiatric Illness: The Emerging Value of Clinical Genetic Testing in Psychiatry. <i>American Journal of Psychiatry</i> , 2017, 174, 1036-1050.	7.2	16
26	The effects of hypertension and body mass index on diffusion tensor imaging in schizophrenia. <i>Schizophrenia Research</i> , 2011, 130, 94-100.	2.0	8
27	A <sc>Multiâ€Phase</sc> Quality Improvement Initiative for the Treatment of Active Delirium in Older Persons. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 216-224.	2.6	8
28	The Course of Functional Decline in Geriatric Patients With Schizophrenia. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 610-619.	1.2	2
29	Pimavanserin in Dementia-Related Psychosis. <i>New England Journal of Medicine</i> , 2021, 385, 372-373.	27.0	1
30	Novel Imaging Strategies for Assessment of Cerebrovascular Involvement. <i>Mount Sinai Journal of Medicine</i> , 2012, 79, 674-682.	1.9	0
31	Reply. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 498.	5.3	0